Molecular profiling in Parkinsonian syndromes: CSF biomarkers

Dorsey, 2007, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 10.1212/01.wnl.0000247740.47667.03 Beck, 2018, Dysregulation of striatal projection neurons in Parkinson’s disease, J. Neural. Transm., 10.1007/s00702-017-1744-5 Mcfarland, 2016, Diagnostic approach to atypical parkinsonian syndromes, Contin. Lifelong Learn. Neurol., 10.1212/CON.0000000000000348 McFarland, 2017, Recognizing atypical parkinsonisms: red flags and therapeutic approaches, Semin. Neurol. Postuma, 2015, MDS clinical diagnostic criteria for Parkinson’s disease, Mov. Disord., 10.1002/mds.26424 McKeith, 2017, Diagnosis and management of dementia with Lewy bodies, Neurology, 10.1212/WNL.0000000000004058 Gilman, 2008, Second consensus statement on the diagnosis of multiple system atrophy, Neurology, 10.1212/01.wnl.0000324625.00404.15 Höglinger, 2017, Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria, MovDisord. Armstrong, 2013, Criteria for the diagnosis of corticobasal degeneration, Neurology, 10.1212/WNL.0b013e31827f0fd1 Ali, 2015, Parkinson’s disease: Chameleons and mimics, PractNeurol. Picillo, 2017, Merging clinical and imaging biomarkers to tackle Parkinson’s disease, MovDisord. Clin. Pract. Wakabayashi, 2007, The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of α-synuclein aggregates, Neuropathology, 10.1111/j.1440-1789.2007.00803.x Anderson, 2006, Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic lewy body disease, J. Biol. Chem., 10.1074/jbc.M600933200 Wakabayashi, 2013, The Lewy body in Parkinson’s disease and related neurodegenerative disorders, Mol. Neurobiol., 10.1007/s12035-012-8280-y Trojanowski, 2007, Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy, Neuropathol. Appl. Neurobiol., 10.1111/j.1365-2990.2007.00907.x Campbell, 2001, The solubility of α-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson’s disease, J. Neurochem. Ingelsson, 2016, Alpha-synuclein oligomers-neurotoxic molecules in Parkinson’s disease and other lewy body disorders, Front. Neurosci., 10.3389/fnins.2016.00408 Parnetti, 2014, Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson’s disease, Front. Aging Neurosci., 10.3389/fnagi.2014.00053 Tokuda, 2010, Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease, Neurology, 10.1212/WNL.0b013e3181fd613b Wennström, 2013, Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy, PLoS ONE, 10.1371/journal.pone.0053250 Bentahir, 2006, Presenilin clinical mutations can affect γ-secretase activity by different mechanisms, J. Neurochem., 10.1111/j.1471-4159.2005.03578.x Dubois, 2014, Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria, Lancet. Neurol., 10.1016/S1474-4422(14)70090-0 Compta, 2011, Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: Which is more important?, Brain, 10.1093/brain/awr031 Kurata, 2007, Enhanced accumulation of phosphorylated α-synuclein in double transgenic mice expressing mutant β-amyloid precursor protein and presenilin-1, J. Neurosci. Res., 10.1002/jnr.21352 Parnetti, 2008, Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with lewy bodies, Biol. Psychiatry., 10.1016/j.biopsych.2008.02.016 Siderowf, 2010, CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease, Neurology, 10.1212/WNL.0b013e3181f39a78 Alves, 2014, CSF Aβ 42 predicts early-onset dementia in Parkinson disease, Neurology, 10.1212/WNL.0000000000000425 Blennow, 2016, Cerebrospinal fluid biomarkers in Alzheimer’s and Parkinson’s diseases-From pathophysiology to clinical practice, Mov. Disord., 10.1002/mds.26656 Mietelska-Porowska, 2014, Tau protein modifications and interactions: Their role in function and dysfunction, Int. J. Mol. Sci., 10.3390/ijms15034671 Irwin, 2012, Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies, Brain, 10.1093/brain/aws013 Yoshida, 2014, Astrocytic inclusions in progressive supranuclear palsy and corticobasal degeneration, Neuropathology, 10.1111/neup.12143 Guo, 2013, XDistinct α-synuclein strains differentially promote tau inclusions in neurons, Cell, 10.1016/j.cell.2013.05.057 Kalaitzakis, 2011, Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes, Neurobiol. Dis., 10.1016/j.nbd.2010.10.005 Borroni, 2011, CSF Alzheimer’s disease-like pattern in corticobasal syndrome: Evidence for a distinct disorder, J. Neurol. Neurosurg. Psychiatry, 10.1136/jnnp.2010.221853 Hall, 2012, Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders, Arch. Neurol., 10.1001/archneurol.2012.1654 Wagshal, 2015, Divergent CSF τ alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy, J. Neurol. Neurosurg. Psychiatry, 10.1136/jnnp-2014-308004 Meredith, 2013, Characterization of novel CSF tau and ptau biomarkers for Alzheimer’s disease, PLoS ONE, 10.1371/journal.pone.0076523 Cicognola, 2019, Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease, Acta Neuropathol., 137, 279, 10.1007/s00401-018-1948-2 Yuan, 2017, Neurofilaments and neurofilament proteins in health and disease, Cold Spring Harb. Perspect. Biol., 9, 10.1101/cshperspect.a018309 Gaetani, 2019, Neurofilament light chain as a biomarker in neurological disorders, J. Neurol. Neurosurg. Psychiatry, 10.1136/jnnp-2018-320106 Bridel, 2019, Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis, JAMA Neurol., 10.1001/jamaneurol.2019.1534 Gaetani, 2018, A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: Analytical validation and clinical evaluation, Alzheimer’s Res. Ther., 10 Parnetti, 2019, CSF and blood biomarkers for Parkinson’s disease, Lancet Neurol., 10.1016/S1474-4422(19)30024-9 Holmberg, 1998, Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease, Mov. Disord., 13, 70, 10.1002/mds.870130116 Brettschneider, 2006, Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes, Mov. Disord., 21, 2224, 10.1002/mds.21124 Thompson, 2019, Review: Fluid biomarkers in the human prion diseases, Mol. Cell Neurosci., 10.1016/j.mcn.2018.12.003 De Vos, 2017, Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke, BMC Neurol., 10.1186/s12883-017-0945-8 Kang, 2016, CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study, Acta Neuropathol., 10.1007/s00401-016-1552-2 Iqbal, 2016, Tau and neurodegenerative disease: The story so far, Nat. Rev. Neurol., 10.1038/nrneurol.2015.225 Portelius, 2015, Cerebrospinal fluid neurogranin: Relation to cognition and neurodegeneration in Alzheimer’s disease, Brain, 10.1093/brain/awv267 Koob, 2014, Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson’s disease, Brain Res., 10.1016/j.brainres.2014.10.013 Bereczki, 2017, Synaptic proteins in CSF relate to Parkinson’s disease stage markers, Npj Park. Dis., 10.1038/s41531-017-0008-2 Selnes, 2017, Impaired synaptic function is linked to cognition in Parkinson’s disease, Ann. Clin. Transl. Neurol., 10.1002/acn3.446 Ransohoff, 2016, How neuroinflammation contributes to neurodegeneration, Science, 353, 777, 10.1126/science.aag2590 Ransohoff, 2012, Innate immunity in the central nervous system, J. Clin. Invest., 10.1172/JCI58644 Sanchez-Guajardo, 2013, Neuroimmunological Processes in Parkinson’s Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity, ASN Neuro., 10.1042/AN20120066 Llorens, 2017, YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias, Mol. Neurodegener., 10.1186/s13024-017-0226-4 Dohgu, 2019, Monomeric α-synuclein induces blood–brain barrier dysfunction through activated brain pericytes releasing inflammatory mediators in vitro, Microvasc. Res., 10.1016/j.mvr.2019.03.005 Schröder, 2018, Immune cell activation in the cerebrospinal fluid of patients with parkinson’s disease, Front. Neurol., 10.3389/fneur.2018.01081 Moors, 2016, Lysosomal dysfunction and α-synuclein aggregation in Parkinson’s disease: diagnostic links, Mov. Disord., 10.1002/mds.26562 Sidransky, 2009, Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease, N. Engl. J. Med., 10.1056/NEJMoa0901281 Nalls, 2013, A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies, JAMA Neurol., 10.1001/jamaneurol.2013.1925 Sklerov, 2017, Frequency of GBA variants in autopsy-proven multiple system atrophy, Mov. Disord. Clin. Pract., 10.1002/mdc3.12481 Cilia, 2016, Survival and dementia in GBA-associated Parkinson’s disease: The mutation matters, Ann. Neurol., 10.1002/ana.24777 O’Regan, 2017, Glucocerebrosidase mutations in parkinson disease, J. Parkinsons. Dis., 10.3233/JPD-171092 Sevlever, 2008, Cathepsin D is the main lysosomal enzyme involved in the degradation of α-synuclein and generation of its carboxy-terminally truncated species, Biochemistry, 10.1021/bi800699v Gegg, 2012, Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains, Ann. Neurol., 10.1002/ana.23614 Chiasserini, 2015, Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies, Mol. Neurodegener., 10.1186/s13024-015-0010-2 Moors, 2019, Characterization of brain lysosomal activities in GBA-related and sporadic Parkinson’s disease and dementia with lewy bodies, Mol. Neurobiol., 10.1007/s12035-018-1090-0 Murphy, 2014, Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease, Brain, 10.1093/brain/awt367 Tasegian, 2017, Origin of α-mannosidase activity in CSF, Int. J. Biochem. Cell Biol., 10.1016/j.biocel.2017.03.016 Paciotti, 2019, Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies, Clin. Chim. Acta., 10.1016/j.cca.2019.03.1627 Parnetti, 2014, Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease, Mov. Disord., 10.1002/mds.25772 Parnetti, 2017, Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson’s disease patients, Mov. Disord., 10.1002/mds.27136 Nicklas, 1992, Mitochondrial mechanisms of neurotoxicity, Ann. N Y Acad. Sci., 10.1111/j.1749-6632.1992.tb24521.x Rocha, 2018, Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease, Neurobiol. Dis., 10.1016/j.nbd.2017.04.004 Larsen, 2018, The genetic architecture of mitochondrial dysfunction in Parkinson’s disease, Cell Tissue Res., 10.1007/s00441-017-2768-8 Kahle, 2009, DJ-1 and prevention of oxidative stress in Parkinson’s disease and other age-related disorders, Free Radic. Biol. Med., 10.1016/j.freeradbiomed.2009.08.003 Neumann, 2004, Pathological properties of the Parkinson’s disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: Relevance for multiple system atrophy and Pick’s disease, Acta Neuropathol., 10.1007/s00401-004-0834-2 Waragai, 2006, Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson’s disease, Biochem. Biophys. Res. Commun., 10.1016/j.bbrc.2006.05.011 Waragai, 2007, Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson’s disease, Neurosci. Lett., 10.1016/j.neulet.2007.08.010 Hong, 2010, DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease, Brain, 10.1093/brain/awq008 Mondello, 2014, CSF α-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders, Park. Relat. Disord., 10.1016/j.parkreldis.2014.01.011 Tateno, 2012, Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (parkinson disease, dementia with lewy bodies, multiple system atrophy) from Alzheimer disease, Alzheimer Dis. Assoc. Disord., 10.1097/WAD.0b013e31823899cc Wang, 2012, Phosphorylated α-synuclein in Parkinson’s disease, Sci. Transl. Med. Tokuda, 2006, Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease, Biochem. Biophys. Res. Commun., 10.1016/j.bbrc.2006.08.024 Buddhala, 2015, Correlation between decreased CSF α-synuclein and Aβ 1–42 in Parkinson disease, Neurobiol. Aging, 10.1016/j.neurobiolaging.2014.07.043 Mollenhauer, 2008, Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration, Exp. Neurol., 10.1016/j.expneurol.2008.06.004 Mollenhauer, 2013, Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects, Neurosci. Lett., 10.1016/j.neulet.2012.11.004 Mollenhauer, 2011, α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study, Lancet Neurol., 10.1016/S1474-4422(11)70014-X Aerts, 2012, CSF α-synuclein does not differentiate between parkinsonian disorders, Neurobiol. Aging, 10.1016/j.neurobiolaging.2010.12.001 Aasly, 2014, Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers, Front. Aging Neurosci., 10.3389/fnagi.2014.00248 Öhrfelt, 2009, Cerebrospinal fluid α-synuclein in neurodegenerative disorders-A marker of synapse loss?, Neurosci. Lett., 10.1016/j.neulet.2008.11.015 Park, 2011, Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease, J. Clin. Neurol., 10.3988/jcn.2011.7.4.215 Zhou, 2015, The diagnostic and differential diagnosis utility of cerebrospinal fluid α -synuclein levels in Parkinson’s disease: A meta-analysis, Parkinsons Dis., 10.1155/2015/567386 Foulds, 2012, Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson’s disease and Dementia with Lewy bodies, Neurobiol. Dis., 10.1016/j.nbd.2011.08.003 Laurens, 2015, Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative, Neurobiol. Dis., 10.1016/j.nbd.2015.05.004 Shi, 2011, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Ann. Neurol., 10.1002/ana.22311 Compta, 2015, Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease, J. Neurol., 10.1007/s00415-014-7560-z Parnetti, 2016, Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson’s diagnosis and prognosis, Biomark. Med., 10.2217/bmm.15.107 Eusebi, 2017, Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson’s disease: A systematic review and meta-analysis, Mov. Disord., 10.1002/mds.27110 Schmitz, 2016, The real-Time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases, Nat. Protoc., 10.1038/nprot.2016.120 Concha-Marambio, 2019, Detection of misfolded α-synuclein aggregates in cerebrospinal fluid by the protein misfolding cyclic amplification platform, Methods Mol. Biol., 10.1007/978-1-4939-9124-2_4 Fairfoul, 2016, Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies, Ann. Clin. Transl. Neurol., 10.1002/acn3.338 Groveman, 2018, Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC, Acta Neuropathol. Commun., 10.1186/s40478-018-0508-2 Shahnawaz, 2017, Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid, JAMA Neurol., 10.1001/jamaneurol.2016.4547 Bellomo, 2019, Dissecting the interactions between human serum albumin and α-synuclein: new insights on the factors influencing α-synuclein aggregation in biological fluids, J. Phys. Chem. B., 10.1021/acs.jpcb.9b02381 Bech, 2012, Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes, Park Relat. Disord., 10.1016/j.parkreldis.2011.08.012 Schoonenboom, 2012, Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort, Neurology, 10.1212/WNL.0b013e31823ed0f0 Andersson, 2011, The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson’s disease dementia, Int. J. Geriatr. Psychiatry, 10.1002/gps.2496 Aerts, 2011, Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome, Mov. Disord., 10.1002/mds.23341 Constantinides, 2017, CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes, J. Neurol. Sci., 10.1016/j.jns.2017.09.039 Feneberg, 2018, Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis, Neurology, 90, e22, 10.1212/WNL.0000000000004761 Bäckström, 2015, Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease, JAMA Neurol., 10.1001/jamaneurol.2015.1449 Herbert, 2015, CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders, Front. Neurol., 6, 91, 10.3389/fneur.2015.00091 Hansson, 2017, Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder, Neurology, 88, 930, 10.1212/WNL.0000000000003680 Olsson, 2013, The glial marker YKL-40 is decreased in synucleinopathies, Mov. Disord., 10.1002/mds.25589 Wennström, 2015, The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer’s but not Parkinson’s disease or dementia with Lewy bodies, PLoS ONE, 10.1371/journal.pone.0135458 Magdalinou, 2015, A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes, J. Neurol. Neurosurg. Psychiatry, 10.1136/jnnp-2014-309562 Parnetti, 2009, Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies, Neurobiol. Dis., 10.1016/j.nbd.2009.03.002 Salvesen, 2012, The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes, Park Relat. Disord., 10.1016/j.parkreldis.2012.03.013 Herbert, 2014, CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls, Park Relat. Disord., 10.1016/j.parkreldis.2013.09.003 Majbour, 2016, Longitudinal changes in CSF alpha-synuclein species reflect Parkinson’s disease progression, Mov. Disord., 10.1002/mds.26754 Hall, 2015, CSF biomarkers and clinical progression of Parkinson disease, Neurology, 10.1212/WNL.0000000000001098 Hall, 2016, Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease, Mov. Disord., 10.1002/mds.26578 Stewart, 2014, Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort, Am. J. Pathol., 10.1016/j.ajpath.2013.12.007 Mollenhauer, 2016, Monitoring of 30 marker candidates in early Parkinson disease as progression markers, Neurology, 10.1212/WNL.0000000000002651 Mollenhauer, 2019, Baseline predictors for progression 4 years after Parkinson’s disease diagnosis in the De Novo Parkinson Cohort (DeNoPa), Mov. Disord., 10.1002/mds.27492 Mollenhauer, 2019, Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson’s disease, Mov. Disord., 10.1002/mds.27806 Terrelonge, 2016, CSF β-amyloid 1–42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease, J. Mol. Neurosci., 10.1007/s12031-015-0647-x Abdelnour, 2016, Alzheimer’s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia, Mov. Disord., 10.1002/mds.26668 Liu, 2015, CSF tau and tau/Aβ42 predict cognitive decline in Parkinson’s disease, Parkinsonism. Relat. Disord., 10.1016/j.parkreldis.2014.12.027 Rojas, 2018, AL-108-231 Investigators, CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP, Neurology, 90, e273, 10.1212/WNL.0000000000004859 Olsson, 2018, Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders, JAMA Neurol., 1 Boxer, 2014, AL-108-231 Investigators, Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial, Lancet Neurol., 13, 676, 10.1016/S1474-4422(14)70088-2 Petzold, 2009, Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy, J. Neurol. Sci., 10.1016/j.jns.2008.12.037 Vanderstichele, 2012, Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative, Alzheimer’s Dement., 10.1016/j.jalz.2011.07.004 Farotti, 2017, Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease, Expert Rev. Mol. Diagn., 10.1080/14737159.2017.1341312 Cicognola, 2015, Preanalytical confounding factors in the analysis of cerebrospinal fluid biomarkers for Alzheimer’s disease: The issue of diurnal variation, Front. Neurol., 10.3389/fneur.2015.00143 Persichetti, 2014, Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid, PLoS ONE, 10.1371/journal.pone.0101453 Kroksveen, 2011, Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics, J. Proteomics., 10.1016/j.jprot.2010.11.010 Shao, 2019, Recent advances and perspectives of metabolomics-based investigations in Parkinson’s disease, Mol. Neurodegener., 10.1186/s13024-018-0304-2